Free tool
FAERS Monitor: Idarubicin Hydrochloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050734 or its brand name (Idarubicin Hydrochloride, Idarubicin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,159
Serious
1,145
99% of reports
Hospitalization
475
Death reported
253
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- myelosuppression195
- febrile neutropenia152
- pyrexia100
- off label use66
- white blood cell count decreased62
- pneumonia61
- platelet count decreased54
- infection53
- neutropenia51
- neutrophil count decreased49
- nausea46
- death43
- sepsis39
- acute myeloid leukaemia38
- drug ineffective36
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 7 |
| 2010 | 8 |
| 2011 | 36 |
| 2012 | 27 |
| 2013 | 10 |
| 2014 | 16 |
| 2015 | 32 |
| 2016 | 16 |
| 2017 | 33 |
| 2018 | 60 |
| 2019 | 52 |
| 2020 | 46 |
| 2021 | 77 |
| 2022 | 155 |
| 2023 | 185 |
| 2024 | 140 |
| 2025 | 149 |
| 2026 | 100 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,000 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelosuppressionSignal | 195 | 98.8 | 86.9 | 18,707 |
| acute myeloid leukaemiaSignal | 38 | 44.4 | 32.4 | 1,565 |
| febrile neutropeniaSignal | 152 | 41.7 | 35.9 | 5,999 |
| neutrophil count decreasedSignal | 49 | 21.8 | 16.6 | 954 |
| white blood cell count decreasedSignal | 62 | 10.4 | 8.2 | 519 |
| platelet count decreasedSignal | 54 | 9.2 | 7.1 | 388 |
| neutropeniaSignal | 51 | 6.8 | 5.2 | 248 |
| infectionSignal | 53 | 6.6 | 5.1 | 250 |
| sepsisSignal | 39 | 6.3 | 4.7 | 171 |
| pyrexiaSignal | 100 | 5.2 | 4.3 | 345 |
| pneumoniaSignal | 61 | 3.4 | 2.7 | 104 |
| off label use | 66 | 1.4 | 1.1 | 6 |
| nausea | 46 | 1.1 | 0.8 | 0 |
| death | 43 | 0.9 | 0.7 | 0 |
| drug ineffective | 36 | 0.5 | 0.4 | 19 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.